Introduction: Hyperkalemia (HK) is a common disorder in patients with heart failure or
chronic kidney disease, and potassium binders (PBs) are recommended to control serum …

Renin-angiotensin-aldosterone system inhibitor (RAASi) therapy has been shown to
improve outcomes among patients with congestive heart failure, diabetes, or renal …

Background: No study has explored the limitations of current long-term management of
hyperkalemia (HK) in outpatient CKD clinics. Methods: We evaluated the association …

Hyperkalemia (HK) is the most common electrolyte disturbance observed in patients with
advanced stages of chronic kidney disease (CKD), is a potentially life-threatening clinical …

Purpose Hyperkalemia is a common metabolic complication of chronic kidney disease
(CKD) and is associated with several serious adverse events. We aimed to treat/prevent …

Chronic hyperkalemia is a major complication of chronic kidney disease (CKD) that occurs
frequently, heralds poor prognosis, and necessitates careful management by the …

Background Gastrointestinal cation exchangers that can bind potassium in the gut, including
sodium polystyrene sulfonate (SPS), calcium polystyrene sulfonate (CPS), patiromer and …

Introduction Hyperkalaemia (HK) is a frequent complication in patients with chronic kidney
disease (CKD) and/or chronic heart failure (CHF). HK must be managed, both to protect …

Hyperkalemia is frequently complicated in patients with advanced chronic kidney disease
(CKD) because kidney is the major route of potassium excretion. Urinary potassium …

Background This analysis used retrospective data from the DISCOVER CKD observational
study (NCT04034992) to describe the burden of and treatment pathways for hyperkalemia …